Vorinostat NEW
| Price | $44 | $86 |
| Package | 200mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: Vorinostat | CAS No.: 149647-78-9 |
| Purity: 99.93% | Supply Ability: 10g |
| Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | Vorinostat |
| Description | Vorinostat (SAHA) is a pan-histone deacetylase (HDAC) inhibitor (IC50=10 nM) with inhibitory activity against HDAC1/2/3/6/7/11. Vorinostat has antitumor activity, induces cell differentiation, blocks the cell cycle and induces apoptosis. |
| Cell Research | Cells were plated onto 100-mm tissue culture plates at a density of 2 × 10^6 for 48 h and then treated with SAHA or equal concentrations of the vehicle. For longer drug exposure times, medium with drug or vehicle were exchanged every 48 h. For wash-out experiments, cells were treated with SAHA daily for 60–72 h (drug and medium were exchanged at 48 h), then SAHA was washed out and replaced with 10% FCS containing DMEM [3]. |
| Animal Research | Athymic Nude-Foxn1nu/nu mice were used in the present study. They were housed at 22°C at a constant light-dark cycle (12-h light, 12-h dark) and had free access to water and rodent chow (4-5% fat, 21% protein). Twelve weeks old male mice (n = 14) were anesthetized with Isofluran and 5 × 10^6 MES-SA cells were injected subcutaneously into the right flank of the animal. Mice from a control group received placebo containing 300 μl of empty HOP-β-CD (2-hydroxypropyl-β-cyclodextrin) vesicles. Another group of mice received vorinostat dissolved in HOP-β-CD at a concentration of 50 mg/kg/day. Both, empty vesicles and vorinostat were administered intraperitoneally, starting on the day 4 after the injection of MES-SA tumor cells. Mice body weight and tumor size (w2 × l × 0.52; measured by caliper) were estimated twice a week. All mice were treated for 21 days and afterward sacrificed by cervical dislocation. Each tumor was isolated as a whole and different tumor parameters (weight, volume, size, and macroscopic appearance) were determined. Finally, tumor slices were cryopreserved and formalin fixed (4%) for further analyses [1]. |
| In vitro | METHODS: Synovial sarcoma cells SW-982 and chondrosarcoma cells SW-1353 were treated with Vorinostat (0.5-15 μM) for 48 h, and cell viability was measured by MST assay. RESULTS: Vorinostat inhibited the proliferation of SW-982 and SW-1353 cells in a dose-dependent manner with IC50s of 8.6 μM and 2.0 μM, respectively. [1] METHODS: Uterine sarcoma cells MES-SA were treated with Vorinostat (3 μM) for 24-72 h. The expression levels of target proteins were detected using Western Blot. RESULTS: There was no difference in the expression of HDAC1 throughout the treatment period, and HDAC2, 3 and 7 showed significant inhibition of expression by Vorinostat. [2] |
| In vivo | METHODS: To detect anti-tumor activity in vivo, Vorinostat (50 mg/kg in HOP-β-CD) was administered intraperitoneally to Nude-Foxn1nu/nu mice bearing uterine sarcoma MES-SA five times per week for twenty-one days. RESULTS: A reduction in tumor growth of more than 50% was observed in the Vorinostat treatment group compared to the placebo group. [1] METHODS: To study the effects in an animal model of true erythrocytosis (PV), Vorinostat (200 mg/kg in 50% PEG-400) was injected intraperitoneally into MxCre;Jak2V617F/+ mice five times per week for two weeks. RESULTS: Vorinostat treatment normalized peripheral blood counts and significantly reduced splenomegaly in Jak2V617F knockout mice.Vorinostat may have therapeutic potential for PV and other JAK2V617F-associated myeloproliferative tumors. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 12.5 mg/mL (47.29 mM), Suspension. Ethanol : 2 mg/mL (7.57 mM), Sonication is recommended. 10% DMSO+30% PEG300 + 5% Tween80 +55% Saline：8 mg/mL : 8 mg/mL (30.27 mM), Solution. DMSO : 262.5 mg/mL (993.11 mM), Sonication is recommended. |
| Keywords | Vorinostat | VirusProtease | Virus Protease | MK-0683 | MK 0683 | Mitophagy | Mitochondrial Autophagy | Inhibitor | inhibit | Human papillomavirus | HPV | Histone deacetylases | HDAC8 | HDAC6 | HDAC3 | HDAC2 | HDAC1 | HDAC | Filovirus | Autophagy | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Manganese chloride (tetrahydrate) | Formamide | Paeonol | Thymidine | Naringin | Alginic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-07-07 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-07 | ||
| $100.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-07-06 | |
| $10.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-06 | |
| $220.00 |
VIP5Y
|
Hebei Dangtong Import and export Co LTD
|
2026-07-01 | |
|
VIP3Y
|
Hangzhou Hyper Chemicals Limited
|
2026-05-29 | ||
| $100.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
|
VIP5Y
|
Zhejiang J&C Biological Technology Co.,Limited
|
2025-12-25 | ||
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2025-12-24 | ||
|
VIP4Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2025-04-04 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY